Abstract
Diabetes mellitus diagnosed during the first 2 years of life differs from the disease in older children regarding its causes, clinical characteristics, treatment options and needs in terms of education and psychosocial support. Over the past decade, new genetic causes of neonatal diabetes mellitus have been elucidated, including monogenic β-cell defects and chromosome 6q24 abnormalities. In patients with KCNJ11 or ABCC8 mutations and diabetes mellitus, oral sulfonylurea offers an easy and effective treatment option. Type 1 diabetes mellitus in infants is characterized by a more rapid disease onset, poorer residual β-cell function and lower rate of partial remission than in older children. Insulin therapy in infants with type 1 diabetes mellitus or other monogenic causes of diabetes mellitus is a challenge, and novel data highlight the value of continuous subcutaneous insulin infusion in this very young patient population. Infants are entirely dependent on caregivers for insulin therapy, nutrition and glucose monitoring, which emphasizes the need for appropriate education and psychosocial support of parents. To achieve optimal long-term metabolic control with low rates of acute and chronic complications, continuous and structured diabetes care should be provided by a multidisciplinary health-care team.
Key Points
-
Diabetes mellitus in infants and children differs in etiology, clinical presentation and therapeutic options; heterogeneous etiologies of diabetes mellitus in infancy include genetic abnormalities, developmental defects and autoimmune disease
-
Monogenic forms of neonatal diabetes mellitus almost always occur in the first 6 months of life and very rarely after 12 months; onset of diabetes mellitus in infants aged >6 months is mostly due to type 1 diabetes mellitus (T1DM)
-
Infants with T1DM exhibit rapid disease onset, poor residual β-cell function and a low rate of transient recovery
-
Insulin is preferentially provided by continuous subcutaneous infusion
-
Treatment with sulfonylurea is possible in most patients with mutations in the genes that encode the ATP-sensitive inward rectifier potassium (KATP) channel
-
Special needs of infants with diabetes mellitus include comprehensive education of caregivers and provision of ongoing diabetes care
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Komulainen, J. et al. Clinical, autoimmune, and genetic characteristics of very young children with type 1 diabetes. Childhood Diabetes in Finland (DiMe) Study Group. Diabetes Care 22, 1950–1955 (1999).
Nimri, R., Phillip, M. & Shalitin, S. Children diagnosed with diabetes during infancy have unique clinical characteristics. Horm. Res. 67, 263–267 (2007).
Aguilar-Bryan, L. & Bryan, J. Neonatal diabetes mellitus. Endocr. Rev. 29, 265–291 (2008).
Metz, C. et al. Neonatal diabetes mellitus: chromosomal analysis in transient and permanent cases. J. Pediatr. 141, 483–489 (2002).
Temple, I. K. et al. Transient neonatal diabetes: widening the understanding of the etiopathogenesis of diabetes. Diabetes 49, 1359–1366 (2000).
Babenko, A. P. et al. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N. Engl. J. Med. 355, 456–466 (2006).
Flanagan, S. E. et al. Mutations in ATP-sensitive K+ channel genes cause transient neonatal diabetes and permanent diabetes in childhood or adulthood. Diabetes 56, 1930–1937 (2007).
Garin, I. et al. Recessive mutations in the INS gene result in neonatal diabetes through reduced insulin biosynthesis. Proc. Natl Acad. Sci. USA 107, 3105–3110 (2010).
Mackay, D. J. & Temple, I. K. Transient neonatal diabetes mellitus type 1. Am. J. Med. Genet. C Semin. Med. Genet. 154C, 335–342 (2010).
Mackay, D. J. et al. Hypomethylation of multiple imprinted loci in individuals with transient neonatal diabetes is associated with mutations in ZFP57. Nat. Genet. 40, 949–951 (2008).
Søvik, O. et al. Familial occurrence of neonatal diabetes with duplications in chromosome 6q24: treatment with sulfonylurea and 40-yr follow-up. Pediatr. Diabetes 10.1111/j.1399-5448.2011.00776.x.
Edghill, E. L. et al. Insulin mutation screening in 1,044 patients with diabetes: mutations in the INS gene are a common cause of neonatal diabetes but a rare cause of diabetes diagnosed in childhood or adulthood. Diabetes 57, 1034–1042 (2008).
Ellard, S. et al. Permanent neonatal diabetes caused by dominant, recessive, or compound heterozygous SUR1 mutations with opposite functional effects. Am. J. Hum. Genet. 81, 375–382 (2007).
Gloyn, A. L. et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N. Engl. J. Med. 350, 1838–1849 (2004).
Sagen, J. V. et al. Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. Diabetes 53, 2713–2718 (2004).
de Wet, H. et al. Increased ATPase activity produced by mutations at arginine-1380 in nucleotide-binding domain 2 of ABCC8 causes neonatal diabetes. Proc. Natl Acad. Sci. USA 104, 18988–18992 (2007).
Proks, P. et al. A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes. Hum. Mol. Genet. 15, 1793–1800 (2006).
Thomas, P. M. et al. Mutations in the sulfonylurea receptor gene in familial persistent hyperinsulinemic hypoglycemia of infancy. Science 268, 426–429 (1995).
Pearson, E. R. et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N. Engl. J. Med. 355, 467–477 (2006).
Rafiq, M. et al. Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations. Diabetes Care 31, 204–209 (2008).
Zwaveling-Soonawala, N. et al. Successful transfer to sulfonylurea therapy in an infant with developmental delay, epilepsy and neonatal diabetes (DEND) syndrome and a novel ABCC8 gene mutation. Diabetologia 54, 469–471 (2011).
Slingerland, A. S. et al. Referral rates for diagnostic testing support an incidence of permanent neonatal diabetes in three European countries of at least 1 in 260,000 live births. Diabetologia 52, 1683–1685 (2009).
Colombo, C. et al. Seven mutations in the human insulin gene linked to permanent neonatal/infancy-onset diabetes mellitus. J. Clin. Invest. 118, 2148–2156 (2008).
Polak, M. et al. Heterozygous missense mutations in the insulin gene are linked to permanent diabetes appearing in the neonatal period or in early infancy: a report from the French ND (Neonatal Diabetes) Study Group. Diabetes 57, 1115–1119 (2008).
Støy, J. et al. Insulin gene mutations as a cause of permanent neonatal diabetes. Proc. Natl Acad. Sci. USA 104, 15040–15044 (2007).
Njølstad, P. R. et al. Neonatal diabetes mellitus due to complete glucokinase deficiency. N. Engl. J. Med. 344, 1588–1592 (2001).
Russo, L. et al. Permanent diabetes during the first year of life: multiple gene screening in 54 patients. Diabetologia 54, 1693–1701 (2011).
Rubio-Cabezas, O. et al. Wolcott–Rallison syndrome is the most common genetic cause of permanent neonatal diabetes in consanguineous families. J. Clin. Endocrinol. Metab. 94, 4162–4170 (2009).
Senée, V. et al. Wolcott-Rallison syndrome: clinical, genetic, and functional study of EIF2AK3 mutations and suggestion of genetic heterogeneity. Diabetes 53, 1876–1883 (2004).
Bennett, C. L. et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 27, 20–21 (2001).
Rubio-Cabezas, O. et al. Clinical heterogeneity in patients with FOXP3 mutations presenting with permanent neonatal diabetes. Diabetes Care 32, 111–116 (2009).
Rubio-Cabezas, O. et al. Permanent neonatal diabetes and enteric anendocrinosis associated with biallelic mutations in NEUROG3. Diabetes 60, 1349–1353 (2011).
Rubio-Cabezas, O. et al. Homozygous mutations in NEUROD1 are responsible for a novel syndrome of permanent neonatal diabetes and neurological abnormalities. Diabetes 59, 2326–2331 (2011).
Wang, J. et al. Mutant neurogenin-3 in congenital malabsorptive diarrhea. N. Engl. J. Med. 355, 270–280 (2006).
Dimitri, P. et al. Novel GLIS3 mutations demonstrate an extended multisystem phenotype. Eur. J. Endocrinol. 164, 437–443 (2011).
Senée, V. et al. Mutations in GLIS3 are responsible for a rare syndrome with neonatal diabetes mellitus and congenital hypothyroidism. Nat. Genet. 38, 682–687 (2006).
Solomon, B. D. et al. Compound heterozygosity for mutations in PAX6 in a patient with complex brain anomaly, neonatal diabetes mellitus, and microophthalmia. Am. J. Med. Genet. A 149A, 2543–2546 (2009).
Wen, J. H. et al. Paired box 6 (PAX6) regulates glucose metabolism via proinsulin processing mediated by prohormone convertase 1/3 (PC1/3). Diabetologia 52, 504–513 (2009).
Bergmann, A. K. et al. Thiamine-responsive megaloblastic anemia: identification of novel compound heterozygotes and mutation update. J. Pediatr. 155, 888–892 e1 (2009).
Labay, V. et al. Mutations in SLC19A2 cause thiamine-responsive megaloblastic anaemia associated with diabetes mellitus and deafness. Nat. Genet. 22, 300–304 (1999).
Kentrup, H., Altmüller, J., Pfäffle, R. & Heimann, G. Neonatal diabetes mellitus with hypergalactosemia. Eur. J. Endocrinol. 141, 379–381 (1999).
Santer, R. et al. Mutations in GLUT2, the gene for the liver-type glucose transporter, in patients with Fanconi–Bickel syndrome. Nat. Genet. 17, 324–326 (1997).
Yoo, H. W., Shin, Y. L., Seo, E. J. & Kim, G. H. Identification of a novel mutation in the GLUT2 gene in a patient with Fanconi–Bickel syndrome presenting with neonatal diabetes mellitus and galactosaemia. Eur. J. Pediatr. 161, 351–353 (2002).
Nicolino, M. et al. A novel hypomorphic PDX1 mutation responsible for permanent neonatal diabetes with subclinical exocrine deficiency. Diabetes 59, 733–740 (2010).
Stoffers, D. A., Zinkin, N. T., Stanojevic, V., Clarke, W. L. & Habener, J. F. Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence. Nat. Genet. 15, 106–110 (1997).
Sellick, G. S. et al. Mutations in PTF1A cause pancreatic and cerebellar agenesis. Nat. Genet. 36, 1301–1305 (2004).
Smith, S. B. et al. Rfx6 directs islet formation and insulin production in mice and humans. Nature 463, 775–780 (2010).
Beardsall, K., Pesterfield, C. L. & Acerini, C. L. Neonatal diabetes and insulin pump therapy. Arch. Dis. Child. Fetal Neonatal Ed. 96, F223–F224 (2011).
Grulich-Henn, J. et al. Entities and frequency of neonatal diabetes: data from the diabetes documentation and quality management system (DPV). Diabet. Med. 27, 709–712 (2010).
Vaziri-Sani, F. et al. ZnT8 autoantibody titers in type 1 diabetes patients decline rapidly after clinical onset. Autoimmunity 43, 598–606 (2010).
Erlich, H. et al. HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. Diabetes 57, 1084–1092 (2008).
Barrett, J. C. et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat. Genet. 41, 703–707 (2009).
Concannon, P. et al. Genome-wide scan for linkage to type 1 diabetes in 2,496 multiplex families from the Type 1 Diabetes Genetics Consortium. Diabetes 58, 1018–1022 (2009).
Holmberg, H., Wahlberg, J., Vaarala, O. & Ludvigsson, J. Short duration of breast-feeding as a risk-factor for beta-cell autoantibodies in 5-year-old children from the general population. Br. J. Nutr. 97, 111–116 (2007).
Norris, J. M. et al. Timing of initial cereal exposure in infancy and risk of islet autoimmunity. JAMA 290, 1713–1720 (2003).
Virtanen, S. M. et al. Early introduction of root vegetables in infancy associated with advanced ss-cell autoimmunity in young children with human leukocyte antigen-conferred susceptibility to type 1 diabetes. Diabet. Med. 28, 965–971 (2011).
Ziegler, A. G., Schmid, S., Huber, D., Hummel, M. & Bonifacio, E. Early infant feeding and risk of developing type 1 diabetes-associated autoantibodies. JAMA 290, 1721–1728 (2003).
Yeung, W. C., Rawlinson, W. D. & Craig, M. E. Enterovirus infection and type 1 diabetes mellitus: systematic review and meta-analysis of observational molecular studies. BMJ 342, d35 (2011).
Zipitis, C. S. & Akobeng, A. K. Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis. Arch. Dis. Child. 93, 512–517 (2008).
Harder, T. et al. Birth weight, early weight gain, and subsequent risk of type 1 diabetes: systematic review and meta-analysis. Am. J. Epidemiol. 169, 1428–1436 (2009).
Vaarala, O., Atkinson, M. A. & Neu, J. The “perfect storm” for type 1 diabetes: the complex interplay between intestinal microbiota, gut permeability, and mucosal immunity. Diabetes 57, 2555–2562 (2008).
Dahlquist, G. G., Nyström, L. & Patterson, C. C. Incidence of type 1 diabetes in Sweden among individuals aged 0–34 years, 1983–2007: an analysis of time trends. Diabetes Care 34, 1754–1759 (2011).
Patterson, C. C., Dahlquist, G. G., Gyürüs, E., Green, A. & Soltész, G. Incidence trends for childhood type 1 diabetes in Europe during 1989–2003 and predicted new cases 2005–20: a multicentre prospective registration study. Lancet 373, 2027–2033 (2009).
Rubio-Cabezas, O., Klupa, T. & Malecki, M. T. Permanent neonatal diabetes mellitus--the importance of diabetes differential diagnosis in neonates and infants. Eur. J. Clin. Invest. 41, 323–333 (2011).
Berhan, Y., Waernbaum, I., Lind, T., Möllsten, A. & Dahlquist, G. Thirty years of prospective nationwide incidence of childhood type 1 diabetes: the accelerating increase by time tends to level off in Sweden. Diabetes 60, 577–581 (2011).
Altamirano-Bustamante, N. et al. Economic family burden of metabolic control in children and adolescents with type 1 diabetes mellitus. J. Pediatr. Endocrinol. Metab. 21, 1163–1168 (2008).
Ying, A. K. et al. Predictors of direct costs of diabetes care in pediatric patients with type 1 diabetes. Pediatr. Diabetes 12, 177–182 (2011).
Icks, A. et al. Direct costs of pediatric diabetes care in Germany and their predictors. Exp. Clin. Endocrinol. Diabetes 112, 302–309 (2004).
Wiréhn, A. B., Andersson, A., Ostgren, C. J. & Carstensen, J. Age-specific direct healthcare costs attributable to diabetes in a Swedish population: a register-based analysis. Diabet. Med. 25, 732–737 (2008).
Bächle, C. et al. Direct diabetes-related costs in young patients with early onset and long-lasting type 1 diabetes [a864]. Diabetologia 54 (Suppl. 1), S353 (2011).
Greeley, S. A. et al. The cost-effectiveness of personalized genetic medicine: the case of genetic testing in neonatal diabetes. Diabetes Care 34, 622–627 (2011).
Hekkala, A., Reunanen, A., Koski, M., Knip, M. & Veijola, R. Age-related differences in the frequency of ketoacidosis at diagnosis of type 1 diabetes in children and adolescents. Diabetes Care 33, 1500–1502 (2010).
Dahlquist, G. & Källén, B. Mortality in childhood-onset type 1 diabetes: a population-based study. Diabetes Care 28, 2384–2387 (2005).
Temple, I. K. & Shield, J. P. 6q24 transient neonatal diabetes. Rev. Endocr. Metab. Disord. 11, 199–204 (2010).
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 33 (Suppl. 1), S62–S69 (2010).
Edghill, E. L., Flanagan, S. E. & Ellard, S. Permanent neonatal diabetes due to activating mutations in ABCC8 and KCNJ11. Rev. Endocr. Metab. Disord. 11, 193–198 (2010).
Bonnefond, A. et al. Molecular diagnosis of neonatal diabetes mellitus using next-generation sequencing of the whole exome. Plos ONE 5, e13630 (2010).
Wambach, J. A., Marshall, B. A., Koster, J. C., White, N. H. & Nichols, C. G. Successful sulfonylurea treatment of an insulin-naive neonate with diabetes mellitus due to a KCNJ11 mutation. Pediatr. Diabetes 11, 286–288 (2010).
Danne, T. et al. A comparison of postprandial and preprandial administration of insulin aspart in children and adolescents with type 1 diabetes. Diabetes Care 26, 2359–2364 (2003).
Danne, T. et al. Parental preference of prandial insulin aspart compared with preprandial human insulin in a basal-bolus scheme with NPH insulin in a 12-wk crossover study of preschool children with type 1 diabetes. Pediatr. Diabetes 8, 278–285 (2007).
Bachran, R. et al. Basal rates and circadian profiles in continuous subcutaneous insulin infusion (CSII) differ for preschool children, prepubertal children, adolescents and young adults. Pediatr. Diabetes 10.1111/j.1399-5448.2011.00777.x.
Szypowska, A., Lipka, M., Błazik, M., Groele, L. & Pańkowska, E. Insulin requirement in preschoolers treated with insulin pumps at the onset of type 1 diabetes mellitus. Acta Paediatr. 98, 527–530 (2009).
Alemzadeh, R., Berhe, T. & Wyatt, D. T. Flexible insulin therapy with glargine insulin improved glycemic control and reduced severe hypoglycemia among preschool-aged children with type 1 diabetes mellitus. Pediatrics 115, 1320–1324 (2005).
Tubiana-Rufi, N. Insulin pump therapy in neonatal diabetes. Endocr. Dev. 12, 67–74 (2007).
Kapellen, T. M. et al. Changes in the use of analogue insulins in 37,206 children and adolescents with type 1 diabetes in 275 German and Austrian centers during the last twelve years. Exp. Clin. Endocrinol. Diabetes 117, 329–335 (2009).
Fox, L. A., Buckloh, L. M., Smith, S. D., Wysocki, T. & Mauras, N. A randomized controlled trial of insulin pump therapy in young children with type 1 diabetes. Diabetes Care 28, 1277–1281 (2005).
Mack-Fogg, J. E., Orlowski, C. C. & Jospe, N. Continuous subcutaneous insulin infusion in toddlers and children with type 1 diabetes mellitus is safe and effective. Pediatr. Diabetes 6, 17–21 (2005).
Pańkowska, E., Błazik, M., Dziechciarz, P., Szypowska, A. & Szajewska, H. Continuous subcutaneous insulin infusion vs. multiple daily injections in children with type 1 diabetes: a systematic review and meta-analysis of randomized control trials. Pediatr. Diabetes 10, 52–58 (2009).
Berghaeuser, M. A. et al. Continuous subcutaneous insulin infusion in toddlers starting at diagnosis of type 1 diabetes mellitus. A multicenter analysis of 104 patients from 63 centres in Germany and Austria. Pediatr. Diabetes 9, 590–595 (2008).
Wilson, D. M. et al. A two-center randomized controlled feasibility trial of insulin pump therapy in young children with diabetes. Diabetes Care 28, 15–19 (2005).
Sulmont, V. et al. Metabolic control in children with diabetes mellitus who are younger than 6 years at diagnosis: continuous subcutaneous insulin infusion as a first line treatment? J. Pediatr. 157, 103–107 (2010).
Müller, G. The molecular mechanism of the insulin-mimetic/sensitizing activity of the antidiabetic sulfonylurea drug Amaryl. Mol. Med. 6, 907–933 (2000).
Hattersley, A. & Pearson, E. Transferring patients with diabetes due to Kir6.2 mutation from insulin to suphonylureas. Diabetes Genes [online], (2011).
Klupa, T. et al. Efficacy and safety of sulfonylurea use in permanent neonatal diabetes due to KCNJ11 gene mutations: 34-month median follow-up. Diabetes Technol. Ther. 12, 387–391 (2010).
Ziegler, R. et al. Frequency of SMBG correlates with HbA1c and acute complications in children and adolescents with type 1 diabetes. Pediatr. Diabetes 12, 11–17 (2011).
Kordonouri, O. et al. Sensor-augmented pump therapy from the diagnosis of childhood type 1 diabetes: results of the Paediatric Onset Study (ONSET) after 12 months of treatment. Diabetologia 53, 2487–2495 (2010).
Deiss, D., Kordonouri, O., Meyer, K. & Danne, T. Long hypoglycaemic periods detected by subcutaneous continuous glucose monitoring in toddlers and pre-school children with diabetes mellitus. Diabet. Med. 18, 337–338 (2001).
Slover, R. H. et al. Effectiveness of sensor-augmented pump therapy in children and adolescents with type 1 diabetes in the STAR 3 study. Pediatr. Diabetes 10.1111/j.1399-5448.2011.00793.x.
Tamborlane, W. V. et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N. Engl. J. Med. 359, 1464–1476 (2008).
Hovorka, R. et al. Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies. BMJ 342, d1855 (2011).
Elleri, D. et al. Automated overnight closed-loop glucose control in young children with type 1 diabetes. Diabetes Technol. Ther. 13, 419–424 (2011).
Keymeulen, B. et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 53, 614–623 (2010).
Ludvigsson, J. et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N. Engl. J. Med. 359, 1909–1920 (2008).
Mastrandrea, L. et al. Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care 32, 1244–1249 (2009).
Wherrett, D. K. et al. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet 378, 319–327 (2011).
Näntö-Salonen, K. et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 372, 1746–1755 (2008).
Knip, M. et al. Dietary intervention in infancy and later signs of beta-cell autoimmunity. N. Engl. J. Med. 363, 1900–1908 (2010).
Couri, C. E. et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 301, 1573–1579 (2009).
Smart, C., Aslander-van Vliet, E. & Waldron, S. Nutritional management in children and adolescents with diabetes. Pediatr. Diabetes 10 (Suppl. 12), 100–117 (2009).
Sauer, C. W. & Kim, J. H. Human milk macronutrient analysis using point-of-care near-infrared spectrophotometry. J. Perinatol. 31, 339–343 (2011).
Detlofson, I., Kroon, M. & Aman, J. Oral bedtime cornstarch supplementation reduces the risk for nocturnal hypoglycaemia in young children with type 1 diabetes. Acta Paediatr. 88, 595–597 (1999).
Lange, K., Sassmann, H., von Schütz, W., Kordonouri, O. & Danne, T. Prerequisites for age-appropriate education in type 1 diabetes: a model programme for paediatric diabetes education in Germany. Pediatr. Diabetes 8 (Suppl. 6), 63–71 (2007).
Swift, P. G. Diabetes education in children and adolescents. Pediatr. Diabetes 10 (Suppl. 12), 51–57 (2009).
McCrimmon, R. J., Gold, A. E., Deary, I. J., Kelnar, C. J. & Frier, B. M. Symptoms of hypoglycemia in children with IDDM. Diabetes Care 18, 858–861 (1995).
Hershey, T. et al. Frequency and timing of severe hypoglycemia affects spatial memory in children with type 1 diabetes. Diabetes Care 28, 2372–2377 (2005).
Wagner, V. M., Grabert, M. & Holl, R. W. Severe hypoglycaemia, metabolic control and diabetes management in children with type 1 diabetes in the decade after the Diabetes Control and Complications Trial—a large-scale multicentre study. Eur. J. Pediatr. 164, 73–79 (2005).
Schoenle, E. J., Schoenle, D., Molinari, L. & Largo, R. H. Impaired intellectual development in children with Type I diabetes: association with HbA(1c), age at diagnosis and sex. Diabetologia 45, 108–114 (2002).
Ferguson, S. C. et al. Influence of an early-onset age of type 1 diabetes on cerebral structure and cognitive function. Diabetes Care 28, 1431–1437 (2005).
Northam, E. A. et al. Neuropsychological profiles of children with type 1 diabetes 6 years after disease onset. Diabetes Care 24, 1541–1546 (2001).
Brink, S. et al. Sick day management in children and adolescents with diabetes. Pediatr. Diabetes 10 (Suppl. 12), 146–153 (2009).
Laffel, L. M. et al. Sick day management using blood 3-hydroxybutyrate (3-OHB) compared with urine ketone monitoring reduces hospital visits in young people with T1DM: a randomized clinical trial. Diabet. Med. 23, 278–284 (2006).
Hatton, D. L., Canam, C., Thorne, S. & Hughes, A. M. Parents' perceptions of caring for an infant or toddler with diabetes. J. Adv. Nurs. 22, 569–577 (1995).
Karges, B. et al. Low discomfort and pain associated with intensified insulin therapy in children and adolescents. Diabetes Res. Clin. Pract. 80, 96–101 (2008).
Haugstvedt, A., Wentzel-Larsen, T., Rokne, B. & Graue, M. Perceived family burden and emotional distress: similarities and differences between mothers and fathers of children with type 1 diabetes in a population-based study. Pediatr. Diabetes 12, 107–114 (2011).
Patton, S. R., Dolan, L. M., Smith, L. B., Thomas, I. H. & Powers, S. W. Pediatric parenting stress and its relation to depressive symptoms and fear of hypoglycemia in parents of young children with type 1 diabetes mellitus. J. Clin. Psychol. Med. Settings http://dx.doi.org/10.1007/s10880-011-9256-1.
Forsander, G. A., Sundelin, J. & Persson, B. Influence of the initial management regimen and family social situation on glycemic control and medical care in children with type I diabetes mellitus. Acta Paediatr. 89, 1462–1468 (2000).
Sullivan-Bolyai, S. et al. Helping other mothers effectively work at raising young children with type 1 diabetes. Diabetes Educ. 30, 476–484 (2004).
Chisholm, V. et al. Predictors of treatment adherence in young children with type 1 diabetes. J. Adv. Nurs. 57, 482–493 (2007).
Winkley, K., Ismail, K., Landau, S. & Eisler, I. Psychological interventions to improve glycaemic control in patients with type 1 diabetes: systematic review and meta-analysis of randomised controlled trials. BMJ 333, 65 (2006).
Pihoker, C., Forsander, G., Wolfsdorf, J. & Klingensmith, G. J. The delivery of ambulatory diabetes care to children and adolescents with diabetes. Pediatr. Diabetes 10 (Suppl. 12), 58–70 (2009).
Fröhlich-Reiterer, E. E. et al. Anthropometry, metabolic control, and follow-up in children and adolescents with type 1 diabetes mellitus and biopsy-proven celiac disease. J. Pediatr. 158, 589–593 e2 (2011).
Warncke, K. et al. Polyendocrinopathy in children, adolescents, and young adults with type 1 diabetes: a multicenter analysis of 28,671 patients from the German/Austrian DPV-Wiss database. Diabetes Care 33, 2010–2012 (2010).
Jansà, M. et al. Telecare in a structured therapeutic education programme addressed to patients with type 1 diabetes and poor metabolic control. Diabetes Res. Clin. Pract. 74, 26–32 (2006).
Gerstl, E. M. et al. Metabolic control as reflected by HbA1c in children, adolescents and young adults with type-1 diabetes mellitus: combined longitudinal analysis including 27,035 patients from 207 centers in Germany and Austria during the last decade. Eur. J. Pediatr. 167, 447–453 (2008).
Margeirsdottir, H. D., Larsen, J. R., Kummernes, S. J., Brunborg, C. & Dahl-Jorgensen, K. The establishment of a new national network leads to quality improvement in childhood diabetes: implementation of the ISPAD Guidelines. Pediatr. Diabetes 11, 88–95 (2010).
Svensson, J., Johannesen, J., Mortensen, H. B. & Nordly, S. Improved metabolic outcome in a Danish diabetic paediatric population aged 0–18 yr: results from a nationwide continuous Registration. Pediatr. Diabetes 10, 461–467 (2009).
de Beaufort, C. E. et al. Continuing stability of center differences in pediatric diabetes care: do advances in diabetes treatment improve outcome? The Hvidoere Study Group on Childhood Diabetes. Diabetes Care 30, 2245–2250 (2007).
Karges, B. et al. Long-acting insulin analogs and the risk of diabetic ketoacidosis in children and adolescents with type 1 diabetes: a prospective study of 10,682 patients from 271 institutions. Diabetes Care 33, 1031–1033 (2010).
Acknowledgements
The authors' work was supported by the BMBF Kompetenznetz Diabetes Mellitus (Competence Network for Diabetes Mellitus) funded by the Federal Ministry of Education and Research (FKZ 01GI0859).
Author information
Authors and Affiliations
Contributions
B. Karges, A. Icks, T. Kapellen and R. W. Holl researched the data for the article. All authors contributed equally to all other aspects of the article.
Corresponding author
Ethics declarations
Competing interests
T. Kapellen declares an association with the following companies: Medtronic (speakers bureau), Roche (speakers bureau). The other authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Karges, B., Meissner, T., Icks, A. et al. Management of diabetes mellitus in infants. Nat Rev Endocrinol 8, 201–211 (2012). https://doi.org/10.1038/nrendo.2011.204
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2011.204
This article is cited by
-
Diabetes management in Wolcott-Rallison syndrome: analysis from the German/Austrian DPV database
Orphanet Journal of Rare Diseases (2020)
-
Case report: maternal mosaicism resulting in inheritance of a novel GATA6 mutation causing pancreatic agenesis and neonatal diabetes mellitus
Diagnostic Pathology (2017)
-
Ketoacidosis at first presentation of type 1 diabetes mellitus among children: a study from Kuwait
Scientific Reports (2016)